利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.015 秒)

    ELECTRIC CONTACT AND FABRICATION METHOD THEREOF
    1.
    发明申请
    ELECTRIC CONTACT AND FABRICATION METHOD THEREOF 审中-公开
    电接触及其制造方法

    公开(公告)号：US20140224628A1

    公开(公告)日：2014-08-14

    申请号：US14235645

    申请日：2012-01-05

    申请人： Jianhua Zhong ,  Wenying Zhang

    发明人： Jianhua Zhong ,  Wenying Zhang

    IPC分类号： H01H1/06 ,  H01H11/04

    CPC分类号： H01H1/06 ,  C23C16/271 ,  C23C16/277 ,  C23C16/278 ,  H01H1/021 ,  H01H11/04 ,  H01H2300/036

    摘要： The present invention discloses an electric contact, comprising a substrate with the surface thereof coated with a nano-diamond film heavily doped with positive trivalent or positive pentavalent elements; the present invention discloses a fabrication method of the above electric contact, comprising the following steps of: (1) fabricating a substrate of the electric contact; (2) performing auxiliary nucleation processing on the electric contact substrate; (3) depositing a nano-diamond film heavily doped with positive trivalent or positive pentavalent elements on the surface of the electric contact substrate. The present invention applies a heavily doped nano-diamond film in an electric contact such that the electric contact has super high heat conductivity, super high frictional wear resistance, high electrical conductivity, high breakdown voltage, high arc ablation resistance and fusion welding resistance, and at the same time, further has an advantage of simple processes, which greatly reduces production cost.

    摘要翻译： 本发明公开了一种电触点，其包括其表面涂覆有重掺杂有正三价或正五价元素的纳米金刚石膜的基底; 本发明公开了上述电接触的制造方法，包括以下步骤：（1）制造电接触的基板; （2）对电接触基板进行辅助成核处理; （3）在电接触衬底的表面上沉积重掺杂正三价或正五价元素的纳米金刚石膜。 本发明在电接触中应用重掺杂的纳米金刚石膜，使得电接触具有超高的导热性，超高摩擦磨损性，高导电性，高击穿电压，高电弧消融电阻和熔焊电阻，以及 同时进一步具有工艺简单的优点，大大降低了生产成本。

    Protein tyrosine kinase inhibitors
    5.
    发明授权
    Protein tyrosine kinase inhibitors 有权
    蛋白酪氨酸激酶抑制剂

    公开(公告)号：US07629347B2

    公开(公告)日：2009-12-08

    申请号：US10531107

    申请日：2003-10-09

    申请人： Wayne R. Danter ,  George Ma ,  Natalie Lazarowych ,  Stephen Houldsworth ,  Martyn Brown ,  Ghenadie Rusu ,  Jianhua Zhong

    发明人： Wayne R. Danter ,  George Ma ,  Natalie Lazarowych ,  Stephen Houldsworth ,  Martyn Brown ,  Ghenadie Rusu ,  Jianhua Zhong

    IPC分类号： C07D401/14 ,  A61K31/506

    CPC分类号： C07D401/14 ,  A61K31/506

    摘要： The present invention relates to uses of the compounds of Formula I as well as pharmaceutically acceptable salts and stereoisomers thereof in methods to treat a variety of tumors in mammals involving abnormal tyrosine kinase signaling, the compounds represented as: wherein R1 and R2 are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ1Z2, wherein Z1 and Z2 are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S, and the aryl and heteroaryl may be further substituted with halogen, alkyl, alkenyl, and alkynyl; with the proviso that when R1 is hydrogen, R2 is a group other than hydrogen.

    摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和立体异构体在治疗涉及异常酪氨酸激酶信号传导的哺乳动物中的各种肿瘤的方法中的用途，所述化合物表示为：其中R1和R2独立地选自 由H组成的组; 烷基; 烯基; 炔基; 卤素; 芳基; 含有N，O或S的杂芳基; 芳基和杂芳基可以进一步被卤素，烷基，烯基和炔基取代; NZ1Z2，其中Z1和Z2独立地选自H和烷基; 和（CO）Y，其中Y选自H，烷基，烯基，炔基，芳基，含有N，O或S的杂芳基，芳基和杂芳基可以进一步被卤素，烷基，烯基和 炔基; 条件是当R 1是氢时，R 2是不同于氢的基团。

    Protein tyrosine kinase inhibitors
    8.
    发明申请
    Protein tyrosine kinase inhibitors 有权
    蛋白酪氨酸激酶抑制剂

    公开(公告)号：US20060111371A1

    公开(公告)日：2006-05-25

    申请号：US10531107

    申请日：2003-10-09

    申请人： Wayne Danter ,  George Ma ,  Natalie Lazarowych ,  Stephen Houldsworth ,  Martyn Brown ,  Ghenadie Rusu ,  Jianhua Zhong

    发明人： Wayne Danter ,  George Ma ,  Natalie Lazarowych ,  Stephen Houldsworth ,  Martyn Brown ,  Ghenadie Rusu ,  Jianhua Zhong

    IPC分类号： A61K31/506

    CPC分类号： C07D401/14 ,  A61K31/506

    摘要： The present invention relates to uses of the compounds of Formula I as well as pharmaceutically acceptable salts and stereoisomers thereof in methods to treat a variety of tumors in mammals involving abnormal tyrosine kinase signalling, the compounds represented as: wherein R1 and R2 are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ1Z2, wherein Z1 and Z2 are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S, and the aryl and heteroaryl may be further substituted with halogen, alkyl, alkenyl, and alkynyl; with the proviso that when R1 is hydrogen, R2 is a group other than hydrogen.

    摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和立体异构体在治疗涉及异常酪氨酸激酶信号传导的哺乳动物中的各种肿瘤的方法中的用途，所述化合物表示为：其中R 1， R 2和R 2独立地选自H; 烷基; 烯基; 炔基; 卤素; 芳基; 含有N，O或S的杂芳基; 芳基和杂芳基可以进一步被卤素，烷基，烯基和炔基取代; NZ 1 Z 2其中Z 1和Z 2独立地选自H和烷基 ; 和（CO）Y，其中Y选自H，烷基，烯基，炔基，芳基，含有N，O或S的杂芳基，芳基和杂芳基可以进一步被卤素，烷基，烯基和 炔基; 条件是当R 1是氢时，R 2是除氢之外的基团。